
Mollie E Wood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6846461/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longitudinal Methods for Modeling Exposures in Pharmacoepidemiologic Studies in Pregnancy. Epidemiologic Reviews, 2022, 43, 130-146.	1.3	13
2	Understanding the Effects of the COVID-19 Pandemic on Infant Development—The Preterm Problem. JAMA Pediatrics, 2022, 176, e215570.	3.3	5
3	DAG With Omitted Objects Displayed (DAGWOOD): a framework for revealing causal assumptions in DAGs. Annals of Epidemiology, 2022, 68, 64-71.	0.9	2
4	The use of glucoseâ€lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States. Endocrinology, Diabetes and Metabolism, 2022, 5, e00319.	1.0	3
5	Association of Maternal Use of Triptans During Pregnancy With Risk of Attention-Deficit/Hyperactivity Disorder in Offspring. JAMA Network Open, 2022, 5, e2215333.	2.8	3
6	Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine. Cephalalgia, 2021, 41, 392-403.	1.8	8
7	Prenatal antidepressant exposure and neurodevelopmental problems in children: to get the right answer, we must ask the right question. Pediatric Research, 2021, 89, 1336-1338.	1.1	0
8	Validation of a Claims-based Algorithm to Identify Pregestational Diabetes Among Pregnant Women in the United States. Epidemiology, 2021, 32, 855-859.	1.2	6
9	Perinatal use of triptans and other drugs for migraine—A nationwide drug utilization study. PLoS ONE, 2021, 16, e0256214.	1.1	1
10	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. Inflammatory Bowel Diseases, 2021, 27, 1427-1434.	0.9	6
11	Prenatal paracetamol exposure and neurodevelopmental outcomes in preschoolâ€aged children. Paediatric and Perinatal Epidemiology, 2020, 34, 247-256.	0.8	16
12	Response to: Modelling paternal exposure as a negative control. International Journal of Epidemiology, 2020, 49, 1054-1055.	0.9	0
13	Fertility treatment and oral contraceptive discontinuation for identification of pregnancy planning in routinely collected health data – an application to analgesic and antibiotic utilisation. BMC Pregnancy and Childbirth, 2020, 20, 731.	0.9	1
14	Modeling exposures of medications used episodically during pregnancy: Triptans as a motivating example. Pharmacoepidemiology and Drug Safety, 2020, 29, 1111-1119.	0.9	4
15	In utero opioid exposure and risk of infections in childhood: A multinational Nordic cohort study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1596-1604.	0.9	4
16	Associations between prenatal acetaminophen exposure and child neurodevelopment: Truth, bias, or a bit of both?. Paediatric and Perinatal Epidemiology, 2020, 34, 233-236.	0.8	7
17	Paternal antidepressant use as a negative control for maternal use: assessing familial confounding on gestational length and anxiety traits in offspring. International Journal of Epidemiology, 2019, 48, 1665-1672.	0.9	13
18	Safe Expectations: Current State and Future Directions for Medication Safety in Pregnancy Research. Clinical Therapeutics, 2019, 41, 2467-2476.	1.1	11

Mollie E Wood

#	Article	IF	CITATIONS
19	Impact of prenatal exposure to benzodiazepines and z-hypnotics on behavioral problems at 5 years of age: A study from the Norwegian Mother and Child Cohort Study. PLoS ONE, 2019, 14, e0217830.	1.1	16
20	Is the association between maternal alcohol consumption in pregnancy and preâ€school child behavioural and emotional problems causal? Multiple approaches for controlling unmeasured confounding. Addiction, 2019, 114, 1004-1014.	1.7	17
21	Analyzing Missing Data in Perinatal Pharmacoepidemiology Research: Methodological Considerations to Limit the Risk of Bias. Clinical Therapeutics, 2019, 41, 2477-2487.	1.1	13
22	Agreement between paternal selfâ€reported medication use and records from a national prescription database. Pharmacoepidemiology and Drug Safety, 2018, 27, 413-421.	0.9	16
23	Prenatal triptan exposure and neurodevelopmental outcomes in 5â€yearâ€old children: Followâ€up from the Norwegian Mother and Child Cohort Study. Paediatric and Perinatal Epidemiology, 2018, 32, 247-255.	0.8	13
24	Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase® European Journal of Clinical Pharmacology, 2018, 74, 627-636.	0.8	9
25	Effect of Time-Dependent Selective Serotonin Reuptake Inhibitor Antidepressants During Pregnancy on Behavioral, Emotional, and SocialÂDevelopment in Preschool-Aged Children. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 200-208.	0.3	49
26	Making fair comparisons in pregnancy medication safety studies: An overview of advanced methods for confounding control. Pharmacoepidemiology and Drug Safety, 2018, 27, 140-147.	0.9	33
27	The Impact of Nondifferential Exposure Misclassification on the Performance of Propensity Scores for Continuous and Binary Outcomes. Medical Care, 2018, 56, e46-e53.	1.1	7
28	Prenatal exposure to antidepressants and increased risk of psychiatric disorders. BMJ: British Medical Journal, 2017, 358, j3950.	2.4	5
29	Patterns and predictors of analgesic use in pregnancy: a longitudinal drug utilization study with special focus on women with migraine. BMC Pregnancy and Childbirth, 2017, 17, 224.	0.9	22
30	Risk of preeclampsia after gestational exposure to selective serotonin reuptake inhibitors and other antidepressants: A study from The Norwegian Mother and Child Cohort Study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1266-1276.	0.9	23
31	Administrative Claims Data Versus Augmented Pregnancy Data for the Study of Pharmaceutical Treatments in Pregnancy. Current Epidemiology Reports, 2017, 4, 106-116.	1.1	30
32	Complex patterns of concomitant medication use: A study among Norwegian women using paracetamol during pregnancy. PLoS ONE, 2017, 12, e0190101.	1.1	3
33	Prenatal triptan exposure and parentâ€reported early childhood neurodevelopmental outcomes: an application of propensity score calibration to adjust for unmeasured confounding by migraine severity. Pharmacoepidemiology and Drug Safety, 2016, 25, 493-502.	0.9	14
34	Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3‥earâ€Old Children: Results from the <scp>N</scp> orwegian <scp>M</scp> other and <scp>C</scp> hild <scp>C</scp> ohort <scp>S</scp> tudy. Paediatric and Perinatal Epidemiology, 2016, 30, 190-200.	0.8	26
35	Longitudinal changes in neurodevelopmental outcomes between 18 and 36â€months in children with prenatal triptan exposure: findings from the Norwegian Mother and Child Cohort Study. BMJ Open, 2016, 6, e011971.	0.8	7
36	Neurodevelopmental problems at 18 months among children exposed to paracetamol <i>in utero</i> : a propensity score matched cohort study. International Journal of Epidemiology, 2016, 45, dyw192.	0.9	37

Mollie E Wood

#	Article	IF	CITATIONS
37	Association of Prenatal Ibuprofen Exposure with Birth Weight and Gestational Age: A Population-Based Sibling Study. PLoS ONE, 2016, 11, e0166971.	1.1	9
38	The Feasibility of an Online Health Program for Community College Students. Community College Journal of Research and Practice, 2012, 36, 637-655.	0.8	2
39	A randomized, controlled trial to test the efficacy of an online, parent-based intervention for reducing the risks associated with college-student alcohol use. Addictive Behaviors, 2012, 37, 25-35.	1.7	34
40	A Randomized Trial of a Webâ€Based Intervention to Improve Migraine Selfâ€Management and Coping. Headache, 2012, 52, 244-261.	1.8	86
41	Health Care Provider Perceptions of Pain Treatment in Hispanic Patients. Pain Practice, 2011, 11, 267-277.	0.9	26
42	A Survey of 100 Community Colleges on Student Substance Use, Programming, and Collaborations. Journal of American College Health, 2011, 59, 563-573.	0.8	17
43	painACTION-Back Pain: A Self-Management Website for People with Chronic Back Pain. Pain Medicine, 2010, 11, 1044-1058.	0.9	106
44	Characteristics of prescription opioid abusers in treatment: Prescription opioid use history, age, use patterns, and functional severity. Journal of Opioid Management, 2010, 6, 239-252.	0.2	27